The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Sultanbaev A.V.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

New opportunities of drug therapy in patients with lung adenocarcinoma with ALK translocation

Authors:

Nasretdinov A.F., Sultanbaev A.V., Menshikov K.V., Musin Sh.I., Sultanbaeva N.I., Izmailov A.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(5): 48‑52

DOI: 10.17116/onkolog2020905148

Views: 1774

Downloaded: 21

Download PDF (RU)
Contact the author
Table of contents

NEW OPPORTUNITIES OF DRUG THERAPY IN PATIENTS WITH LUNG ADENOCARCINOMA WITH ALK TRANSLOCATION
NEW OPPORTUNITIES OF DRUG THERAPY IN PATIENTS WITH LUNG ADENOCARCINOMA WITH ALK TRANSLOCATION

To cite this article:

Nasretdinov AF, Sultanbaev AV, Menshikov KV, Musin ShI, Sultanbaeva NI, Izmailov AA. New opportunities of drug therapy in patients with lung adenocarcinoma with ALK translocation. P.A. Herzen Journal of Oncology. 2020;9(5):48‑52. (In Russ.)
https://doi.org/10.17116/onkolog2020905148

 
Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata

The paper deals with an analysis the efficacy and toxicity of alectinib, by using an example of treating clinical cases of anaplastic lymphoma kinase (ALK)-mutated non-small cell lung tumors. It describes two clinical cases of using alectinib in patients with lung adenocarcinoma with ALK translocation. The paper presents an individual approach to treating the patient and information on the side effects of different ALK inhibitors. The experience with alectinib demonstrates that the drug can be used long in the presence of its high efficiency and controlled safety profile.

Keywords:

lung cancer
ALK mutation
hepatotoxicity
tyrosine kinase inhibitors
alectinib

Authors:

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Sultanbaev A.V.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

14.07.2020

Accepted:

30.07.2020

List of references:

  1. Barlesi F, Mazieres J, Merlio JP. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-1426. https://doi.org/10.1016/S0140-6736(16)00004
  2. Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, Tsimafeyeu I, Tjulandin S. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Lung Cancer. 2017;103:17-23.  https://doi.org/1010.1016/j.lungcan.2016.11.001
  3. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36-54.  https://doi.org/1010.3978/j.issn.2218-6751.2014.05.01
  4. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105-1111. https://doi.org/1010.1200/JCO.2012.44.5353
  5. Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423-430.  https://doi.org/1010.1111/1759-7714.12613
  6. Zhang I, Zaorsky NG, Palmer JD. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16:510-521. 
  7. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. https://doi.org/1010.1056/NEJMoa1408440
  8. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233-1243. https://doi.org/10.1016/j.jtho.2019.03.007
  9. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinibin untreated ALK-positive non — small-cell lung cancer. N Engl J Med. 2017;377(9):829-838.  https://doi.org/1010.1056/NEJMoa1704795
  10. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. https://doi.org/1010.1056/NEJMoa1716948
  11. Dumont D, Dô P, Lerouge D, Planchard G, Riffet M, Dubos-Arvis C, Danhier S, Gervais R. Off-label use of crizotinib as a neoadjuvant treatment for a young patient when conventional chemotherapy gave no benefits in stage IIIA non-small cell lung cancer. Am J Case Rep. 2017;18:890-893.  https://doi.org/1010.12659/ajcr.903528
  12. Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, Takahashi Y. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. J Thorac Dis. 2018;10(3):170-174.  https://doi.org/1010.21037/jtd.2018.02.03
  13. Li J, Yuan Z, Wang Q, Fan W, Zhang G. Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. Medicine (Baltimore). 2019;98(1):e13726. https://doi.org/1010.1097/MD.0000000000013726

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.